Attached files
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of AzurRx
BioPharma, Inc. (the “Company”) on Form 10-Q for the period ended
September 30, 2018 as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), I, Johan M. (Thijs) Spoor, Chief
Executive Officer of the Company, and Maged Shenouda, Chief
Financial Officer of the Company, each certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:
|
(1) The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934;
and
|
|
(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of
operations of the Company.
|
Date: November 9, 2018
|
/s/ Johan
M. (Thijs) Spoor
|
|
Johan M. (Thijs) Spoor
President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
|
|
/s/ Maged
Shenouda
Maged Shenouda
Chief Financial Officer
(Principal Financial and Accounting Officer)
|